# Dabrafenib plus trametinib in previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer

Source: https://onco.cc/key-papers/paper-planchard-dabrafenib-trametinib-first-line-lancet-oncol-2017/  
OnCo record `paper-planchard-dabrafenib-trametinib-first-line-lancet-oncol-2017` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Used as first treatment, dabrafenib plus trametinib shrank tumours in almost two thirds of patients with BRAF V600E-mutant lung cancer and controlled the disease for over a year, supporting its use before chemotherapy.

## Summary

First-line cohort of the phase 2 multicohort study: 36 patients with untreated BRAF V600E-mutant metastatic non-small-cell lung cancer received dabrafenib plus trametinib.

Objective response was 64 percent with a median progression-free survival of 10.9 months and median overall survival of 24.6 months at the initial report; updated analyses showed durable benefit.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: The Lancet Oncology
- Year: 2017
- DOI: 10.1016/S1470-2045(17)30679-4
- Authors: Planchard D, Smit EF, Groen HJM, et al.
- Findings: Objective response 64 percent.; Median progression-free survival 10.9 months; median overall survival 24.6 months.
- What it means: BRAF plus MEK inhibition is a standard first-line option for BRAF V600E lung cancer, with chemo-immunotherapy as the alternative or subsequent line.
- Caveats: Small single-arm cohort; no comparison with chemo-immunotherapy.

## Sources

- Lancet Oncol 2017: https://doi.org/10.1016/S1470-2045(17)30679-4
- PubMed: https://pubmed.ncbi.nlm.nih.gov/28919011/

## Connected records

- cancers: [BRAF V600E-mutant non-small-cell lung cancer](https://onco.cc/cancers/braf-v600e-nsclc/)
- drugs: [Dabrafenib](https://onco.cc/drugs/dabrafenib/), [Trametinib](https://onco.cc/drugs/trametinib/)
- journals: [The Lancet Oncology](https://onco.cc/journals/lancet-oncology/)

---
JSON: https://onco.cc/api/v1/entities/paper-planchard-dabrafenib-trametinib-first-line-lancet-oncol-2017.json